Muromonab CD3
Mechanism :
Blocks function of CD3 in T lymphocytes.
Indication :
- Acute Allograft Rejection or Acute Graft-Vs-Host Disease Treatment
Contraindications :
Hypersensitivity to any murine-derived products, Anti-mouse Ab titres = 1:1000, Uncontrolled heart failure or fluid overload, uncontrolled hypertension, history of seizures, pregnancy, breastfeeding.
Dosing :
Oral:
<30 kg
2.5 mg IV daily x 10-14 days.
>30 kg:
5 mg IV daily x 10-14 days.
May titrate daily by 2.5 mg to achieve CD3+cells <25/cumm and serum muromonab-CD3 >800 ng/mL.
Adverse Effect :
Pyrexia, chills, dyspnea, nausea, chest pain, diarrhea, tremors, wheezing, headache, tachycardia, hypotension, vomiting, anaphylaxis.
Interaction :
Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of live vaccines.
Renal Dose :
Dose in Renal Impairment GFR (mL/min)
| 20-50 | Dose as in normal renal function |
| 10-20 | Dose as in normal renal function |
| <10 | Dose as in normal renal function |
Dose in Patients undergoing Renal Replacement Therapies
| CAPD | Unlikely to be dialysed. Dose as in normal renal function |
| HD | Not dialysed. Dose as in normal renal function |
| HDF/High flux | Unknown dialysability. Dose as in normal renal function |
| CAV/VVHD | Unknown dialysability. Dose as in normal renal function |
Hepatic Dose :
No dosage adjustments are recommended.